FDA — authorised 7 October 2021
- Application: NDA214487
- Marketing authorisation holder: CHEMOCENTRYX
- Local brand name: TAVNEOS
- Indication: CAPSULE — ORAL
- Status: approved
🇺🇸 Tavneos in United States
FDA authorised Tavneos on 7 October 2021
Marketing authorisation
Tavneos in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Rare Disease approved in United States
Frequently asked questions
Is Tavneos approved in United States?
Yes. FDA authorised it on 7 October 2021.
Who is the marketing authorisation holder for Tavneos in United States?
CHEMOCENTRYX holds the US marketing authorisation.